Adagene Inc.(ADAG)Earnings, Financials & Key Ratios
ADAG•NASDAQ
Price updated Jun 13, 2026
AboutAdagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.Show more
- Revenue$103K-99.4%
- EBITDA-$35M-55.6%
- Net Income-$33M-76.4%
- EPS (Diluted)-0.95-75.9%
- Gross Margin-797.49%-897.5%
- EBITDA Margin-33937.92%-27204.7%
- Operating Margin-34835.42%-26498.9%
- Net Margin-32386.45%-30859.3%
- ROE-55.21%-123.9%
- Debt/Equity0.37+15.8%
- Interest Coverage-42.20-97.1%
ADAG Key Insights
Adagene Inc. (ADAG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 86 (top 14%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 26.5% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ADAG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADAG Price & Volume
Adagene Inc. (ADAG) stock price & volume — 10-year historical chart
Loading chart...
ADAG Growth Metrics
Adagene Inc. (ADAG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-26.47%
3 Years-78.35%
TTM-99.43%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-192.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-188.43%
Return on Capital
10 Years-42.46%
5 Years-46.21%
3 Years-48.18%
Last Year-53.12%
ADAG Recent Earnings
Adagene Inc. (ADAG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (57%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
Apr 1, 2026EPS
$0.07
Est $0.28
+75.0%
Revenue
$8M
Est $18M
-56.1%
Q2 2025
Mar 24, 2025EPS
$0.55
Est $0.33
-67.7%
Revenue
$103,204
Q3 2024
Jul 25, 2024EPS
$0.19
Est $0.41
+53.0%
Revenue
—
Q2 2024
Mar 31, 2024EPS
$0.19
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 1, 2026 | $0.07vs $0.28+75.0% | $8Mvs $18M-56.1% |
| Q2 2025 | Mar 24, 2025 | $0.55vs $0.33-67.7% | $103,204 |
| Q3 2024 | Jul 25, 2024 | $0.19vs $0.41+53.0% | — |
| Q2 2024 | Mar 31, 2024 | $0.19 | — |
Based on last 12 quarters of dataView full earnings history →
ADAG Peer Comparison
Adagene Inc. (ADAG) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZLAB | 1.89B | 17.07 | -10.67 | 15.33% | -39.29% | -24.32% | 0.31 | |
 BCAB | 4.87M | 3.86 | -0.08 | -81.82% | -25.31% | |||
 IMVT | 6.9B | 33.62 | -12.14 | -68.16% | 0.00 | |||
 XNCR | 904.26M | 12.33 | -9.94 | 13.65% | -185.71% | -28.77% | 0.30 | |
 MGTX | 888.13M | 9.59 | -6.75 | 144.57% | -151.12% | -368.19% | ||
 RCUS | 2.4B | 23.80 | -7.23 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 137.42M | 3.30 | -970.59 | 10.37% | 52.16% | |||
 NKTR | 1.16B | 59.38 | -6.10 | -43.89% | -284.18% | -87% | 1.66 |
Compare ADAG vs Peers
Adagene Inc. (ADAG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADAG Income Statement
Adagene Inc. (ADAG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.51M | 480K | 480K | 10.18M | 9.29M | 18.11M | 103.2K | 103.2K |
Revenue Growth % | - | -68.24% | 0% | 2019.85% | -8.67% | 94.9% | -99.43% | -99.43% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.23M |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 1.51M▲ 0% | 480K▼ 68.2% | 480K▲ 0.0% | 10.18M▲ 2019.8% | 9.29M▼ 8.7% | 18.11M▲ 94.9% | -823.04K▼ 104.5% | -1.12M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | -797.49% | -1088.49% |
Gross Profit Growth % | - | -68.24% | 0% | 2019.85% | -8.67% | 94.9% | -104.54% | - |
Operating Expenses | 18.85M | 19.65M | 19.65M | 82.54M | 93.21M | 41.83M | 36.05M | 60.76M |
OpEx % of Revenue | 1247.09% | 4093.68% | 4093.68% | 811.18% | 1003.08% | 230.97% | 34935.42% | - |
Selling, General & Admin | 2.77M | 3.44M | 3.44M | 14.44M | 11.87M | 8.67M | 7.27M | 10.98M |
SG&A % of Revenue | 182.98% | 716.23% | 716.23% | 141.91% | 127.78% | 47.89% | 7047.53% | - |
Research & Development | 16.08M | 16.21M | 16.21M | 68.1M | 81.34M | 36.64M | 28.78M | 46.96M |
R&D % of Revenue | 1064.11% | 3377.45% | 3377.45% | 669.26% | 875.3% | 202.3% | 27887.88% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -3.48M | 0 | 0 |
Operating Income | -17.33M▲ 0% | -19.17M▼ 10.6% | -19.17M▲ 0.0% | -72.36M▼ 277.5% | -83.92M▼ 16.0% | -23.72M▲ 71.7% | -35.95M▼ 51.6% | -60.84M▲ 0% |
Operating Margin % | -1147.09% | -3993.68% | -3993.68% | -711.18% | -903.08% | -130.97% | -34835.42% | -58950.51% |
Operating Income Growth % | - | -10.59% | 0% | -277.49% | -15.97% | 71.74% | -51.57% | - |
EBITDA | -16.43M | -18.35M | -18.31M | -71.24M | -82.49M | -22.51M | -35.03M | -59.41M |
EBITDA Margin % | -1086.94% | -3823.53% | -3814.84% | -700.12% | -887.7% | -124.29% | -33937.92% | -57568.32% |
EBITDA Growth % | - | -11.73% | 0.23% | -289.05% | -15.8% | 72.71% | -55.59% | -162.07% |
D&A (Non-Cash Add-back) | 909K | 816.69K | 858.41K | 1.13M | 1.43M | 1.21M | 926.25K | 1.43M |
EBIT | -15.18M | -16.29M | -42.2M | -71.11M | -78.82M | -16.15M | -32.59M | -54.94M |
Net Interest Income | 619.63K | 784.58K | 427.12K | -287.6K | -315.82K | 3.18M | 2.95M | 4.62M |
Interest Income | 710.71K | 922.68K | 629.29K | 76.17K | 377.5K | 4.28M | 3.8M | 5.79M |
Interest Expense | 91.08K | 138.1K | 202.16K | 363.76K | 693.32K | 1.11M | 851.87K | 1.17M |
Other Income/Expense | 2.07M | 2.74M | 754.38K | 887.77K | 4.41M | 6.46M | 2.51M | 5.38M |
Pretax Income | -15.27M▲ 0% | -16.43M▼ 7.6% | -16.43M▲ 0.0% | -71.48M▼ 335.0% | -79.51M▼ 11.2% | -17.25M▲ 78.3% | -33.44M▼ 93.8% | -55.46M▲ 0% |
Pretax Margin % | -1010.22% | -3423.4% | -3423.4% | -702.45% | -855.65% | -95.27% | -32403.46% | -53735.07% |
Income Tax | -547K | 0 | 3.16K | 1.7M | 459.06K | 1.69M | -17.55K | -16.4K |
Effective Tax Rate % | 3.58% | 0% | -0.02% | -2.38% | -0.58% | -9.8% | 0.05% | 0.03% |
Net Income | -14.72M▲ 0% | -17.29M▼ 17.5% | -16.44M▲ 5.0% | -73.18M▼ 345.2% | -79.97M▼ 9.3% | -18.95M▲ 76.3% | -33.42M▼ 76.4% | -55.44M▲ 0% |
Net Margin % | -974.03% | -3602.89% | -3424.06% | -719.18% | -860.59% | -104.61% | -32386.45% | -53719.18% |
Net Income Growth % | - | -17.49% | 4.96% | -345.24% | -9.28% | 76.31% | -76.41% | -192.62% |
Net Income (Continuing) | -15.27M | -16.43M | -42.4M | -73.18M | -79.97M | -18.95M | -33.42M | -55.44M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.51▲ 0% | -0.49▲ 67.5% | -0.59▼ 20.4% | -2.29▼ 288.1% | -2.31▼ 0.9% | -0.54▲ 76.6% | -0.95▼ 75.9% | -1.47▲ 0% |
EPS Growth % | - | 67.55% | -20.41% | -288.14% | -0.87% | 76.62% | -75.93% | -188.43% |
EPS (Basic) | -1.51 | -0.49 | -0.59 | -2.29 | -2.31 | -0.55 | -0.95 | - |
Diluted Shares Outstanding | 9.7M | 35.33M | 28.07M | 32.02M | 34.65M | 35.03M | 36.02M | 37.69M |
Basic Shares Outstanding | 9.7M | 35.33M | 28.07M | 32.02M | 34.65M | 34.64M | 36.02M | 37.69M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ADAG Balance Sheet
Adagene Inc. (ADAG) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 51.82M | 103.92M | 79.1M | 185.95M | 149.32M | 113.44M | 87.78M | 65.36M |
Cash & Short-Term Investments | 49.06M | 100.53M | 75.15M | 174.39M | 143.76M | 109.93M | 85.19M | 62.83M |
Cash Only | 16.06M | 92.53M | 75.15M | 174.39M | 143.76M | 109.93M | 85.19M | 62.83M |
Short-Term Investments | 33M | 8M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.43M | 2.14M | 132.4K | 7.51M | 619.43K | 222.03K | 8.31K | 2.45K |
Days Sales Outstanding | 345.44 | 1.63K | 100.68 | 269.27 | 24.33 | 4.47 | 29.39 | 37.29 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 2.49M | 3.78M | 2.7M | 527.71K | 2.33M |
Total Non-Current Assets | 2.6M | 1.97M | 5.17M | 3.56M | 3.08M | 2.29M | 1.51M | 1.15M |
Property, Plant & Equipment | 2.55M | 1.88M | 2.07M | 3.49M | 2.97M | 2.2M | 1.41M | 1.12M |
Fixed Asset Turnover | 0.59x | 0.26x | 0.23x | 2.92x | 3.12x | 8.23x | 0.07x | 0.07x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 197.07K | 197.07K | 7.17M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -147.88K | -109.84K | -4.07M | 69.28K | 109.57K | 84.89K | 103.5K | 37.44K |
Total Assets | 54.42M▲ 0% | 105.89M▲ 94.6% | 84.26M▼ 20.4% | 189.51M▲ 124.9% | 152.4M▼ 19.6% | 115.73M▼ 24.1% | 89.27M▼ 22.9% | 66.52M▲ 0% |
Asset Turnover | 0.03x | 0.00x | 0.01x | 0.05x | 0.06x | 0.16x | 0.00x | 0.00x |
Asset Growth % | - | 94.59% | -20.42% | 124.9% | -19.58% | -24.06% | -22.86% | -107.89% |
Total Current Liabilities | 10.35M | 7.18M | 16.15M | 29.82M | 55.08M | 31.46M | 38.18M | 28.52M |
Accounts Payable | 558.98K | 712.71K | 1.81M | 3.32M | 3.67M | 3.09M | 4.24M | 3.63M |
Days Payables Outstanding | - | - | - | - | - | - | - | 1.09K |
Short-Term Debt | 2.33M | 1.04M | 5.02M | 4.5M | 13.62M | 8.4M | 17.79M | 6.76M |
Deferred Revenue (Current) | 32.98K | 993.38K | 725.54K | 5.5M | 15.11M | 52.88K | 0 | 0 |
Other Current Liabilities | 1.41M | 2.07M | 6.2M | 11.62M | 21.43M | 18.54M | 56.27K | 16.34M |
Current Ratio | 5.01x | 14.47x | 4.90x | 6.24x | 2.71x | 3.61x | 2.30x | 2.29x |
Quick Ratio | 5.01x | 14.47x | 4.90x | 6.24x | 2.71x | 3.61x | 2.30x | 2.29x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -1.05K |
Total Non-Current Liabilities | 85.1M | 155.72M | 157.51M | 3.13M | 14.23M | 13.71M | 559.64K | 88.71K |
Long-Term Debt | 0 | 1.52M | 2.97M | 2.99M | 14.15M | 13.54M | 417.34K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 53.83K | 173.66K | 142.3K | 459.18K |
Deferred Tax Liabilities | 0 | 0 | 0 | 44.16K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 85.1M | 154.2M | 154.54M | 94.11K | 28.72K | 0 | 0 | 0 |
Total Liabilities | 95.44M | 162.9M | 173.65M | 32.95M | 69.31M | 45.17M | 38.74M | 28.61M |
Total Debt | 2.33M | 2.56M | 7.98M | 7.49M | 27.97M | 22.31M | 18.49M | 6.85M |
Net Debt | -13.73M | -89.98M | -67.17M | -166.9M | -115.79M | -87.63M | -66.7M | -55.98M |
Debt / Equity | - | - | - | 0.05x | 0.34x | 0.32x | 0.37x | 0.18x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.12x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.94x |
Interest Coverage | -190.31x | -138.81x | -94.82x | -198.93x | -121.04x | -21.41x | -42.20x | -46.92x |
Total Equity | -41.03M▲ 0% | -57.01M▼ 39.0% | -89.39M▼ 56.8% | 156.56M▲ 275.1% | 83.09M▼ 46.9% | 70.56M▼ 15.1% | 50.52M▼ 28.4% | 37.91M▲ 0% |
Equity Growth % | - | -38.96% | -56.8% | 275.14% | -46.93% | -15.08% | -28.4% | -124.7% |
Book Value per Share | -4.23 | -1.61 | -3.19 | 4.89 | 2.40 | 2.01 | 1.40 | 1.01 |
Total Shareholders' Equity | -41.03M | -57.01M | -89.39M | 156.56M | 83.09M | 70.56M | 50.52M | 37.91M |
Common Stock | 1.52K | 1.52K | 1.89K | 5.63K | 5.5K | 5.55K | 5.89K | 5.89K |
Retained Earnings | -46.83M | -63.26M | -105.66M | -178.83M | -258.81M | -277.75M | -311.18M | -324.66M |
Treasury Stock | 78.55M | 147.41M | -7.17M | -619.61K | -4 | -4 | 0 | 0 |
Accumulated OCI | -410.69K | -344.89K | -350.98K | -93.98K | -849.3K | -1.8M | -526.9K | -1.7M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADAG Cash Flow Statement
Adagene Inc. (ADAG) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -14.26M | -18.15M | -28.53M | -43.41M | -48.61M | -28.45M | -29.7M | -47.54M |
Operating CF Margin % | -943.95% | -3781.99% | -5943.69% | -426.67% | -523.12% | -157.11% | -28778.91% | - |
Operating CF Growth % | - | -27.26% | -57.16% | -52.17% | -11.97% | 41.47% | -4.38% | -66.05% |
Net Income | -15.27M | -16.43M | -42.4M | -73.18M | -79.97M | -18.95M | -33.42M | -55.44M |
Depreciation & Amortization | 909K | 816.69K | 858.41K | 1.13M | 1.45M | 1.21M | 926.25K | 1.48M |
Stock-Based Compensation | 126.54K | 611.71K | 10.13M | 18.68M | 10.52M | 7.27M | 4.91M | 6.92M |
Deferred Taxes | 0 | 0 | 0 | 622.43K | -44.16K | 0 | 0 | 0 |
Other Non-Cash Items | -547.85K | -1.23M | 645.02K | -9.95K | -2.5M | -1.44M | -222.24K | -415.07K |
Working Capital Changes | 513.83K | -1.92M | 2.23M | 9.35M | 21.94M | -16.55M | -1.89M | -98.29K |
Change in Receivables | 268.67K | -480K | 480K | -3M | 6.89M | 397.4K | 213.72K | 213.72K |
Change in Inventory | 0 | -2.59M | 925.17K | 6.02M | 0 | 0 | 0 | 0 |
Change in Payables | 389.12K | 153.74K | 1.1M | 1.51M | 344.51K | -572.37K | 1.15M | 530.96K |
Cash from Investing | -29.51M | 24.86M | 7.07M | -2.51M | -686.05K | -77.36K | 1.11M | 1.35M |
Capital Expenditures | -514.7K | -151.83K | -935.2K | -2.51M | -690.94K | -85.01K | -33.58K | -42.35K |
CapEx % of Revenue | 34.06% | 31.63% | 194.83% | 24.67% | 7.44% | 0.47% | 32.54% | 41.04% |
Acquisitions | 5.17K | 7.7K | 7.93K | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 5.17K | 25.01M | 7.93K | 0 | 4.89K | 7.66K | 169 | 230.06K |
Cash from Financing | 51.06M | 69.69M | 4.44M | 145.36M | 17.82M | -5.37M | 3.77M | -8.58M |
Debt Issued (Net) | 1.06M | 234.68K | 5.02M | -702.86K | 21.48M | -5.37M | -3.42M | -15.07M |
Equity Issued (Net) | 0 | 1000K | 0 | 1000K | -1000K | 0 | 1000K | 1.02M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -2.36M | -3.98M | 0 | 0 | 0 |
Other Financing | 50M | 459.8K | -580.6K | -1.37M | 323.21K | 5.5K | -137.3K | -855.34K |
Net Change in Cash | 7.32M▲ 0% | 76.47M▲ 944.4% | -17.38M▼ 122.7% | 99.24M▲ 670.9% | -30.63M▼ 130.9% | -33.82M▼ 10.4% | -24.74M▲ 26.9% | -47.11M▲ 0% |
Free Cash Flow | -14.78M▲ 0% | -18.31M▼ 23.9% | -29.46M▼ 61.0% | -45.92M▼ 55.9% | -49.3M▼ 7.4% | -28.54M▲ 42.1% | -29.73M▼ 4.2% | -47.59M▲ 0% |
FCF Margin % | -978.01% | -3813.62% | -6138.52% | -451.34% | -530.55% | -157.58% | -28811.45% | -46109.48% |
FCF Growth % | - | -23.86% | -60.96% | -55.86% | -7.36% | 42.11% | -4.19% | -253.59% |
FCF per Share | -1.52 | -0.52 | -1.05 | -1.43 | -1.42 | -0.81 | -0.83 | -1.26 |
FCF Conversion (FCF/Net Income) | 0.97x | 1.05x | 1.74x | 0.59x | 0.61x | 1.50x | 0.89x | 0.86x |
Interest Paid | 0 | 0 | 0 | 0 | 603.68K | 1.05M | 778.51K | 778.51K |
Taxes Paid | 0 | 0 | 0 | 0 | 2.43M | 1.38M | 33.95K | 33.95K |
ADAG Key Ratios
Adagene Inc. (ADAG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -217.89% | -66.74% | -24.66% | -55.21% | -146.23% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | 257.67% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | -797.49% | -1088.49% |
| Net Margin | -3602.89% | -3424.06% | -719.18% | -860.59% | -104.61% | -32386.45% | -53719.18% |
| Debt / Equity | - | - | 0.05x | 0.34x | 0.32x | 0.37x | 0.18x |
| Interest Coverage | -138.81x | -94.82x | -198.93x | -121.04x | -21.41x | -42.20x | -46.92x |
| FCF Conversion | 1.05x | 1.74x | 0.59x | 0.61x | 1.50x | 0.89x | 0.86x |
| Revenue Growth | -68.24% | 0% | 2019.85% | -8.67% | 94.9% | -99.43% | -99.43% |
Related:ADAG Dividend History·ADAG Revenue History·ADAG Price History·ADAG P/E History·ADAG Financial Ratios·ADAG Institutional Holders
ADAG Frequently Asked Questions
Adagene Inc. (ADAG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Adagene Inc. (ADAG) reported $0.1M in revenue for fiscal year 2024. This represents a 93% decrease from $1.5M in 2018.
Adagene Inc. (ADAG) saw revenue decline by 99.4% over the past year.
Adagene Inc. (ADAG) reported a net loss of $55.4M for fiscal year 2024.
Dividend & Returns
Adagene Inc. (ADAG) has a return on equity (ROE) of -55.2%. Negative ROE indicates the company is unprofitable.
Adagene Inc. (ADAG) had negative free cash flow of $47.6M in fiscal year 2024, likely due to heavy capital investments.